OncoSec Medical

ONCS NASDAQ
2.830
+0.030
+1.07%
Closed 16:00 06/17 EDT
Open
2.830
Prev Close
2.800
High
2.850
Low
2.717
Volume
145.74K
Avg Vol (3M)
167.90K
52 Week High
19.60
52 Week Low
2.300
% Turnover
1.39%
Market Cap
29.64M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers OncoSec Medical ONCS stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. As of July 31, 2016, the Company was pursuing two Phase II trials: ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma and ImmunoPulse IL-12 plus pembrolizumab in patients with advanced, metastatic melanoma. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple negative breast cancer. Its ImmunoPulse product candidates are based on its deoxyribonucleic acid (DNA)-based immunotherapy technology, which is designed to stimulate the human immune system, resulting in systemic anti-tumor immune responses.
MORE >

Recently

Name
Price
%Change